Key facts
- Windgap Medical’s last known valuation is $149.5M (Aug 2021).
- It has raised $73.7M across 9 recorded rounds; the latest was Early Stage VC ($12.7M) in Nov 2023.
- Notable investors include MassChallenge, National Institutes of Health, Bantam Group, Launchpad Venture Group, SideCar Angels — 27 tracked in total.
- Windgap Medical has filed 14 Form Ds with the SEC since 2014, most recently Jan 2026 ($12.7M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 9 rounds
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Windgap Medical
Funding rounds
9 roundsAbout Windgap Medical
Developer of auto-injectors and medicine delivery devices designed to treat patients with severe allergies. The company's auto-injectors are filled with heat-stable epinephrine to improve temperature resilience and shelf lives of medications, enabling physicians to inject it into a patient suffering from anaphylaxis due to an acute allergic attack.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2011
- Employees
- 19
- Website
- windgapmedical.com/
- Ownership
- Privately Held (backing)
Windgap Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Windgap Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Windgap Medical in its N-PORT filings yet. We sweep new filings monthly.